Obagi Medical Products

What Obagi Medical Products does

Obagi Medical Products, founded in 1988 and headquartered in Long Beach, California, is a professional-grade skincare company that develops and commercializes clinically-validated dermatological products and aesthetic injectables. The product portfolio spans prescription treatments (Obagi Nu-Derm Rx, Tretinoin, Obagi-C Rx with hydroquinone and L-ascorbic acid), core cosmeceutical lines (Professional-C Vitamin C serums, ELASTIDERM firming, CLENZIDERM M.D. acne, Nu-Derm Fx, Daily Hydro-Drops with Isoplentix, Sun Shield mineral SPF), specialty collections (NU-GEN longevity-focused serum with proprietary AGE CTRL Complex combining NAD+, NMN, and Niacinamide; SUZANOBAGIMD), and FDA-approved hyaluronic acid dermal fillers (saypha MagIQ and saypha ChIQ) developed via a licensing partnership with Croma-Pharma GmbH. The company serves both professional channels (board-certified dermatologists, plastic surgeons, and med spas) and direct-to-consumer end markets, with products priced $30-$525 and a Subscribe & Save program offering 15% recurring discounts.

The business operates a dual distribution model: a physician-dispensed channel enabled by the Physician Finder tool and the ALOHA Program real-world evidence platform embedded across 9,000+ aesthetic clinics via Aesthetic Record, 120+ Platinum Dermatology locations, and partnerships including Schweiger Dermatology, ProMD Health, VIO Med Spa, It's a Secret Med Spa, DermFx, Next Health, and Moxie; and a direct-to-consumer channel through Obagi.com, Amazon, and authorized retailers. Obagi was the first skincare brand to clinically test products on all skin types and tones (SKINCLUSION initiative), generating 35 years of clinical evidence and Allure Best of Beauty awards in 2023, 2024, and 2025. The company operates internationally with localized websites in Vietnam, Thailand, Singapore, and India, though the Japan business was divested to Rohto Pharmaceutical for $82.5M in March 2026.

In July 2026, Waldencast plc completed the sale of Obagi Medical to private equity firm Bridgepoint Group for up to $460 million, with Waldencast founders Michel Brousset and Hind Sebti and CFO Manuel Manfredi transitioning to lead the company under Bridgepoint ownership. Waldencast reported Obagi Medical FY2025 net revenue of $72 million, with Q3 2025 revenue up 10.1% YoY driven by e-commerce and international markets. The company employs 251-500 people and is rebuilding as a focused aesthetics platform around the Croma-Pharma injectable franchise and recent product launches targeting the US medical aesthetics market projected to grow from $40 billion to $137 billion by 2033.

Name

Obagi Medical Products

Legal name

Obagi Cosmeceuticals LLC

Website

https://obagi.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

251–500 employees

Short description

Obagi Medical Products is a 35-year-old professional skincare company that develops clinically-validated medical-grade topicals, prescription Rx treatments, and FDA-approved hyaluronic acid injectable fillers, sold through dermatologists, med spas, and direct-to-consumer e-commerce channels.

Ownership category

akta.pro rank

Product category

Professional Medical Skincare

NAICS

Cosmetics, Beauty Supplies, and Perfume Retailers (456120), Health and Personal Care Retailers (456)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

akta.pro secondary industries

Treatment Skincare (Serums, Actives, Acne & Anti-aging) (CRABAAAB), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)

Keywords

• Medical-grade skincare
• Cosmeceutical products
• Professional skincare line
• Dermal filler injectables
• Anti-aging skincare

Headquarters

HQ city

Long Beach

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Personnel, Technology or R&D, Operations

Revenue model

1. Professional/Physician-dispensed Skincare: Medical-grade skincare products sold through dermatologists, aesthetic physicians, and med spas. Products include prescription Obagi Rx line (tretinoin, hydroquinone-based treatments) and professional-grade formulations.
2. Direct-to-Consumer E-commerce: Consumer sales through Obagi.com, Amazon, and authorized retailers. Products range from $30-$380 with subscription option (Subscribe & Save) offering 15% discount for recurring orders.
3. Injectable Aesthetic Products: FDA-approved hyaluronic acid dermal fillers (saypha MagIQ) administered by licensed healthcare practitioners. Product only available through qualified providers, not direct consumer purchase.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Core offering

Obagi Medical Products manufactures and sells medical-grade cosmeceutical skincare products and FDA-approved injectable hyaluronic acid dermal fillers. The portfolio spans prescription and OTC skincare systems targeting aging, hyperpigmentation, acne, and texture concerns, plus the saypha MagIQ and ChIQ injectable filler line developed with Croma-Pharma. Products are distributed through physicians, med spas, authorized retailers, and direct-to-consumer e-commerce.

Product overview

Obagi Medical Products is a professional skincare company offering medical-grade, clinically-proven skincare products and aesthetic injectables. The portfolio spans prescription treatments (Obagi Nu-Derm Rx with hydroquinone, Tretinoin, Obagi-C Rx), core cosmeceutical lines (Professional-C Vitamin C serums, ELASTIDERM firming line, CLENZIDERM M.D. acne systems, Nu-Derm Fx skin brightening), specialty collections (NU-GEN longevity-focused Cellular Renewal Serum, SUZANOBAGIMD formulated by Dr. Suzan Obagi, OBAGI360 retinol, Sun Shield SPF), and FDA-approved injectable aesthetics (saypha MagIQ and ChIQ hyaluronic acid fillers from partnership with Croma-Pharma). Products are distributed through physicianFinder channels, authorized retailers, and direct-to-consumer e-commerce. The company operates a Build Your Own Bundle customization system with 15% Subscribe & Save program and recently expanded into longevity skincare and injectable aesthetics markets.

Differentiator

Problem solved

Functional benefit

Products and services

• CLENZIDERM M.D. Resurfacing Multi-Acid Peel Pads At-home resurfacing peel pads with a synergistic blend of glycolic, phytic, salicylic, and mandelic acids designed to smooth texture, brighten skin, and minimize visible pores.
• NU-GEN Cellular Renewal Serum Longevity-focused serum featuring proprietary AGE CTRL Complex with NAD+, NMN, and Niacinamide. Clinically proven to visibly rewind skin age by up to six years and addresses nine signs of skin aging.
• Obagi saypha MagIQ Hyaluronic Acid Dermal Filler FDA-approved injectable hyaluronic acid dermal filler designed to smooth moderate-to-severe facial wrinkles and folds such as nasolabial folds. Features most usable HA, most consistent particle size, and smallest distribution for predictable outcomes.
• Professional-C Serum Collection (10%, 15%, 20%) Vitamin C antioxidant serums available in 10%, 15%, and 20% concentrations. Designed to neutralize free radicals, minimize fine lines, and brighten skin tone using L-ascorbic acid. Professional-C Serum 20% won the Allure Best of Beauty Award 2025.
• ELASTIDERM Collection Firming and lifting skincare line including Facial Serum, Eye Cream, De-Puffing Eye Serum, Neck and Décolleté Lifting Concentrate, and Lift Up & Sculpt Facial Moisturizer. Uses Bi-Mineral Contour Complex for elasticity support.
• Obagi Nu-Cil Eyelash Enhancing Serum Eyelash enhancing serum containing prostaglandin analog and biotin. Clinically shown to visibly improve eyelash thickness and length in approximately 12 weeks.
• Obagi Nu-Cil Eyebrow Boosting Serum Eyebrow boosting serum with prostaglandin analogs and biotin. Designed to extend hair growth phase and strengthen strands for visibly thicker eyebrows.
• Obagi Nu-Cil BioStim Scalp Serum Scalp serum designed to support scalp health and hair follicle fortification for visibly denser, fuller hair. Part of PRP scalp treatment pairing recommendations.
• Obagi Nu-Derm Rx System Prescription skincare system containing 4% hydroquinone for skin brightening. Includes Clear, Blender, Sunfader, and Tretinoin formulations. Available only through authorized retailers with prescription.
• Obagi Tretinoin Prescription retinoid gel and cream in 0.025%, 0.05%, and 0.1% concentrations. Indicated for topical treatment of acne vulgaris.
• Obagi-C Rx System Prescription Vitamin C skincare system combining 4% hydroquinone with 10% L-ascorbic acid for skin brightening and rejuvenation.
• Sun Shield Mineral UV Barrier Protect SPF 40 100% mineral sunscreen with broad-spectrum UVA/UVB protection. Contains antioxidants, ceramides, and squalane for barrier support. Designed for sensitive and post-procedure skin.
• Daily Hydro-Drops Collection Hydrating facial serum and eye gel cream using Isoplentix Technology. Delivers instant hydration and supports skin radiance.
• Obagi Hydrate Collection Moisturizer line including Hydrate Facial Moisturizer, Hydrate Luxe Ultra Moisture-Rich Cream, and Hydrate Light Weightless Gel Cream for various skin types. Hydrate Light Weightless Gel Cream won the Allure Best of Beauty Award 2024.
• Obagi Nu-Derm Fx System Skin brightening system with Clear Fx, Blend Fx, and Exfoderm products. Transforms skin by noticeably evening out and brightening complexion.
• Obagi-C Fx Collection Vitamin C skincare combining L-ascorbic acid with arbutin for skin brightening and enhanced even skin tone.
• SUZANOBAGIMD Collection Skincare line developed by Dr. Suzan Obagi including Super Antioxidant Serum, Moisture Restore Cream, Claribright Brightening Lotion, Foaming Cleanser, Balancing Toner, and Retivance Skin Rejuvenating Complex.
• OBAGI360 Retinol Collection Retinol skincare products including 0.5% and 1.0% Smoothing Retinol serums with entrapped retinol and advanced slow-release technology.
• Lip Therapy Collection Lip care products including Soothe & Protect Lip Treatment Broad Spectrum SPF 30 and AHA+PHA Smoothing Micro-Peel.
• CLENZIDERM M.D. Systems Acne treatment line including Daily Lightweight Foaming Blemish Cleanser, Pore Therapy Exfoliating BHA Toner, and Therapeutic Lotion for visible acne results in 4 weeks.
• Obagi Blue Brilliance Triple Acid Peel Professional-grade chemical peel with salicylic, glycolic, and lactic acids for minimizing dull and uneven skin to reveal brighter complexion.
• OBAGI REBALANCE Skin Barrier Recovery Cream Barrier recovery moisturizer designed to support skin barrier health and restore compromised skin.
• Obagi saypha ChIQ Injectable FDA-approved injectable hyaluronic acid gel for cheek augmentation and correction of midface contour deficiencies in adults over 21. Utilizes proprietary MACRO Core Technology developed by Croma-Pharma.

Quantifiable outcome

• 97% of participants agreed peel pads smoothed skin texture after 4 weeks
• +7 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Croma-Pharma GmbHcoreTechnology or Integration · 1 July 2026Croma-Pharma developed and received FDA approval for Obagi saypha® ChIQ™ injectable hyaluronic acid gel for cheek augmentation, following the earlier approval of saypha® MagIQ™. The partnership enables Obagi Medical to commercialize Croma's injectable portfolio in the US market.
• ProMD HealthcoreStrategic or Co-development Partner · 19 March 2026ProMD Health collaboration in ALOHA Program to conduct real-world clinical evaluation of saypha MagIQ hyaluronic acid filler across 17 multi-state practice locations, combining clinical education with hands-on injector experience.
• Rohto PharmaceuticalminorChannel Partner/ Reseller/ Distributor · 16 March 2026Rohto Pharmaceutical acquired exclusive rights to sell Obagi in Japan for $82.5 million, reducing Waldencast's net debt and enabling focus on core markets.
• Schweiger DermatologycoreStrategic or Co-development Partner · 27 February 2026Schweiger Dermatology is a key ALOHA Program partner conducting a Phase 4 clinical study led by Dr. David Goldberg at Hackensack location and real-world evaluation program at select Schweiger aesthetic locations.
• It's a Secret Med SpacoreStrategic or Co-development Partner · 25 February 2026ALOHA Program partnership evaluating saypha MagIQ across 15 locations using structured data capture and clinical protocols to translate FDA pivotal trial data into everyday premium med spa practice.
• Aesthetic RecordcoreTechnology or Integration · 17 February 2026Aesthetic Record partnership in ALOHA Program leveraging EMR, charting, analytics, and integrated practice management tools across network of over 9,000 aesthetic clinics to capture data and evaluate Obagi protocols.
• DermFxcoreStrategic or Co-development Partner · 6 February 2026DermFx partnership in ALOHA Program for structured evaluation of saypha MagIQ in real-world settings across Southern California med spa locations, translating FDA pivotal trial data into clinical practice.
• MoxiecoreStrategic or Co-development Partner · 5 February 2026Moxie strategic partnership in ALOHA Program collecting standardized data on filler integration into scalable aesthetic workflows using software, marketing, coaching, and compliance tools across supported aesthetic practices.
• VIO Med SpacoreStrategic or Co-development Partner · 30 January 2026VIO Med Spa as launch partner for ALOHA Program conducting real-world clinical evaluations of saypha MagIQ across national network of med spa locations, launching at VIO University's expert-led training event.
• Next HealthcoreStrategic or Co-development Partner · 28 January 2026Next Health partnership in ALOHA Program conducting multi-site assessment of saypha MagIQ filler across wellness and longevity centers, leveraging integration of advanced injectables with holistic protocols and data-driven outcomes.
• Platinum Dermatology PartnerscoreStrategic or Co-development Partner · 26 January 2026Platinum Dermatology Partners is the launch partner for the ALOHA (Aesthetics Leadership with Obagi's Hyaluronic Acid) Program, conducting hands-on evaluations and clinical initiatives across over 120 dermatology locations. Initial findings to be presented at Platinum Summit in Dallas.
• Novaestiq Corp.coreTechnology or Integration · 23 July 2025Waldencast acquired Novaestiq Corp. as part of its strategy to secure US rights to Saypha® injectables and expand into medical aesthetics through Obagi Medical brand.

Scale indicators14 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Galderma: Global dermatology and medical aesthetics incumbent (parent of Alastin, Cetaphil, Restylane) — competes broadly with Obagi across prescription skincare, OTC dermocosmetics, and now injectables via saypha.
• Allergan Aesthetics (AbbVie): Owner of SkinMedica, Alastin (via Galderma prior), Botox, and the Juvederm filler franchise — a broad incumbent competing with Obagi in both professional skincare and the injectable HA filler market that saypha MagIQ and ChIQ target.

Direct peers

• SkinCeuticals: L'Oréal-owned medical-grade skincare brand built around Vitamin C serums (CE Ferulic) and physician-dispensed distribution — the closest direct competitor to Obagi's Professional-C line and physician channel strategy.
• PCA Skin: Colgate-Palmolive-owned professional skincare brand with chemical peels, hydroquinone-based brightening systems, and a physician-dispensed channel — directly comparable to Obagi's CLENZIDERM and Nu-Derm Fx lines.
• iS Clinical: Medical-grade skincare brand with active treatment serums, cancer-care supportive skincare, and a physician/spa channel — overlapping with Obagi on treatment serums, peels, and professional distribution.
• Alastin Skincare: Galderma/AbbVie-owned professional skincare brand tightly integrated with in-office aesthetic procedures (fillers, lasers) — a direct peer to Obagi's treatment-pairing and post-procedure positioning around saypha MagIQ and ChIQ injectables.
• Revision Skincare: Medical-grade skincare brand with peptide and retinoid-based anti-aging products sold through physicians and med spas — a direct peer in the professional anti-aging serum category alongside Obagi Professional-C and ELASTIDERM.
• SkinMedica: Allergan Aesthetics/AbbVie-owned medical-grade skincare brand sold through physicians with a similar anti-aging and hyperpigmentation portfolio, competing head-to-head with Obagi Nu-Derm and ELASTIDERM lines.
• EltaMD: Colgate-Palmolive-owned medical-grade skincare brand strong in mineral sunscreens and post-procedure care — directly comparable to Obagi's Sun Shield SPF 40 and sensitive/post-procedure positioning.
• Colorescience: Mineral-based medical-grade skincare and sun protection brand sold through dermatologists and med spas — comparable to Obagi in physician channel positioning and mineral sunscreen category overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/obagimedical
• Xx.com/obagi
• Facebookfacebook.com/Obagi
• LinkedInlinkedin.com/company/305632

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Obagi Medical Products